MBRX
Moleculin Biotech, Inc.4.6900
+0.1201+2.63%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
9.71MP/E (TTM)
-Basic EPS (TTM)
-49.75Dividend Yield
0%Recent Filings
8-K
45th enrollment triggers data unblinding
Moleculin Biotech hit the 45th patient enrollment in its pivotal Phase 2B/3 MIRACLE trial of AnnAraC for relapsed/refractory AML on March 23, 2026, kicking off final prep for mid-2026 interim unblinding. Blinded data already show 40% remission rate in tough patients, many venetoclax-failures. Data readout looms. Trial speeds to 90 patients by Q3.
8-K
MIRACLE 40% CRc; cash to Q3
Moleculin Biotech reported 2025 net loss of $33.7M on $25.1M operating expenses, with cash at $8.9M sufficient into Q3 2026 alongside $8.3M fresh financing. MIRACLE trial hit 40% blinded CRc rate in first 30 R/R AML patients, including venetoclax failures. 45-patient interim unblinding on track for mid-2026. Cash burn demands more funding.
10-K
FY2025 results
Moleculin Biotech posted FY2025 net loss of $33.6M, up from $26.0M in FY2024, driven by non-cash warrant volatility including $24.4M gain on fair value changes offset by $31.0M issuance loss; R&D fell to $15.9M from $17.7M as sponsored research eased, while G&A ticked to $9.1M. No revenue yet, cash at $8.9M supports MIRACLE trial—Phase 2B/3 for AnnAraC in 2L R/R AML—into Q3 2026 post-Q1 warrant exercises. MIRACLE dosed 35 subjects by Feb 2026 with blinded preliminary CRc 40% (n=30), interim unblindings mid- and H2 2026. Cash burn slowed slightly; warrant raises funded ops. Geopolitical risks threaten Eastern Europe sites.
8-K
Warrant inducement nets $8.3M
Moleculin Biotech entered inducement letters on February 19, 2026, prompting holders to exercise existing warrants for 2,122,652 shares at $3.90, yielding ~$8.3M gross proceeds. In exchange, the company issued Series H warrants for 6,367,956 shares at a price floored at $0.962, exercisable post-shareholder approval for five years. Cash bolsters operations, but dilution looms large.
AMLX
Amylyx Pharmaceuticals, Inc.
12.31-0.25
ANEB
Anebulo Pharmaceuticals, Inc.
2.23+0.02
ANNX
Annexon, Inc.
4.80-0.11
ANTX
AN2 Therapeutics, Inc.
1.16-0.01
ARMP
Armata Pharmaceuticals, Inc.
5.72-0.44
ATHA
Athira Pharma, Inc.
3.88+0.03
MBIO
Mustang Bio, Inc.
1.07-0.06
MOLN
Molecular Partners AG
4.18+0.19
MRKR
Marker Therapeutics, Inc.
1.27-0.12
VIRX
Viracta Therapeutics, Inc.
0.01+0.00